GCS-100, a citrus pectin-derived specific gal-3 antagonist, has proven to be effective in restoring or augmenting drug sensitivity in myeloma, large B-cell lymphoma and B-chronic lymphocytic leukemia [37-40]. Here, LGALS3 is linked to B-cell chronic lymphocytic leukemia.